These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33637332)

  • 1. Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects.
    Jeon JY; Kim SY; Moon SJ; Oh K; Lee J; Kim B; Song GS; Kim MG
    Clin Ther; 2021 Apr; 43(4):722-734. PubMed ID: 33637332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial.
    Du Y; Yu L; Deng B; Li Q; Hu J; Li L; Xu Y; Song L; Xie F; Wang Y; Chen Y; Liu C; Zhai X; Lu Y
    Clin Drug Investig; 2024 May; 44(5):343-355. PubMed ID: 38615091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Interactions Between Tegoprazan and Naproxen, Aceclofenac, and Celecoxib in Healthy Korean Male Subjects.
    Moon SJ; Shin N; Kang M; Kim B; Kim MG
    Clin Ther; 2022 Jul; 44(7):930-944.e1. PubMed ID: 35787943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
    Yoon K; Kim N; Lee JW; Yoon H; Shin CM; Park YS; Lee DH
    Helicobacter; 2020 Jun; 25(3):e12685. PubMed ID: 32141173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
    Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
    Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori.
    Delchier JC; Malfertheiner P; Thieroff-Ekerdt R
    Aliment Pharmacol Ther; 2014 Jul; 40(2):171-7. PubMed ID: 24863854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
    Gisbert JP; Gisbert JL; Marcos S; Grávalos RG; Carpio D; Pajares JM
    Aliment Pharmacol Ther; 1999 Oct; 13(10):1311-6. PubMed ID: 10540045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days.
    Knigge K; Kelly C; Peterson WL; Fennerty MB
    Aliment Pharmacol Ther; 1999 Mar; 13(3):323-6. PubMed ID: 10102965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
    Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
    PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
    Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
    Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
    Sakurai Y; Shiino M; Okamoto H; Nishimura A; Nakamura K; Hasegawa S
    Adv Ther; 2016 Sep; 33(9):1519-35. PubMed ID: 27432383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study.
    O'Morain C; Borody T; Farley A; De Boer WA; Dallaire C; Schuman R; Piotrowski J; Fallone CA; Tytgat G; Mégraud F; Spénard J;
    Aliment Pharmacol Ther; 2003 Feb; 17(3):415-20. PubMed ID: 12562455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication.
    Spénard J; Aumais C; Massicotte J; Brunet JS; Tremblay C; Grace M; Lefebvre M
    Br J Clin Pharmacol; 2005 Oct; 60(4):374-7. PubMed ID: 16187969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
    Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant
    Lee JW; Kim N; Nam RH; Yu JE; Son JH; Lee SM; Lee DH
    Gut Liver; 2021 Jan; 15(1):53-60. PubMed ID: 33191308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates.
    Sotudehmanesh R; Malekzadeh R; Fazel A; Massarrat S; Ziad-Alizadeh B; Eshraghian MR
    J Gastroenterol Hepatol; 2001 Mar; 16(3):264-8. PubMed ID: 11339416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of metronidazole, tetracycline and bismuth in healthy volunteers after oral administration of compound tablets containing a combination of metronidazole, tetracycline hydrochloride and bismuth oxide.
    Wu Y; Ding L; Huang NY; Wen AD; Liu B; Li WB
    Drug Res (Stuttg); 2015 Feb; 65(2):74-81. PubMed ID: 24764254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pylera for the eradication of Helicobacter pylori infection.
    Saleem A; Qasim A; O'Connor HJ; O'Morain CA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.